Study of the Effect of ITCA 650 on the PK/PD of Oral Contraceptive in Healthy Female Subjects

Intarcia Therapeutics

Status and phase

Completed

Phase 1

Conditions

Healthy Adult Premenopausal Female Volunteers

Treatments

Drug: ITCA 650 20/60 mcg/day, ITCA placebo

Drug: ITCA placebo, ITCA 650 20/60 mcg/day

Study type

Interventional

Funder types

Industry

Identifiers

NCT02641990

ITCA 650-CLP-116

Details and patient eligibility

About

A Phase 1, randomized, double-blind, placebo-controlled, crossover study to assess the effect of ITCA 650 on the pharmacokinetics (PK) of once daily administration of Levora® (ethinyl estradiol 0.3 mg (EE) and levonorgestrel 0.15 mg (LNG) in healthy premenopausal female subjects.

Enrollment

28 patients

Sex

Female

Ages

18 to 45 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Women of childbearing potential.
Use of a combination oral contraceptive ≥3 months immediately prior to screening.
Willing to use an additional adequate method of contraception during the study and until 1 additional menstrual cycle following the end-of-study (EOS) visit. Adequate methods of contraception for women of child bearing potential (WOCBP) include: mechanical products (ie, intrauterine device [IUD]-copper IUD); or barrier methods (eg, diaphragm, condoms, cervical cap) with spermicide.
Body mass index (BMI) ≥19 and ≤32 kg per meter squared.
Weight ≥50 and ≤100 kg.
Non-smoker or ex-smoker for >6 months prior to screening (and has stopped using other nicotine products ≥2 weeks prior to screening).

Exclusion criteria

History of type 1 or type 2 diabetes.
Received implanted contraceptives within 6 months prior to screening or injected contraceptives within 12 months prior to screening.
History or evidence, within the last 6 months prior to the Screening Visit, of myocardial infarction, coronary revascularization (coronary artery bypass grafting or percutaneous coronary intervention), unstable angina, or cerebrovascular accident or stroke.
History of uncontrolled hypertension.
History or evidence of acute or chronic pancreatitis.
History of liver disease.
History of medullary thyroid cancer or a personal or family history of multiple endocrine neoplasia type 2.
Poor thyroid, liver, or renal function.
Weight loss surgery or requires weight loss medications.
History of malignancy (not including basal or squamous cell carcinoma of the skin with past 5 years). (Subjects who have been disease free for 5 years may be included.)
Estrogen-dependent growths; undiagnosed vaginal bleeding.
History of active alcohol or substance abuse.
Regular daily consumption of more than 12 g of alcohol in any form.
Excessive in xanthine consumption (more than 5 cups of coffee or equivalent per day).
Treatment with medications that affect GI motility.
Any condition that would affect drug transit time or absorption (eg, gastrointestinal bypass surgery, partial or total gastrectomy, small bowel resection, chronic diarrhea, vagotomy, chronic gastroesophageal reflux disease, malabsorption, colostomy, Crohn's disease, ulcerative colitis, or celiac sprue).
History of hypersensitivity to exenatide.
Contraindications or warnings according to the specific label(s) for EE and/or LNG therapy.
Women that are pregnant, lactating, or planning to become pregnant.
Any use of anticoagulants with the exception of those given in prophylaxis prior to surgical intervention.
History of or positive results on screening tests for hepatitis B and/or hepatitis C and/or human immunodeficiency virus (HIV).
Recent surgery or planned in-patient surgery, dental procedure, or hospitalization during the study.
History of migraine if aged >35 years or has focal symptoms associated with migraine.
History of thrombophlebitis, thromboembolic disorders, or deep vein thrombophlebitis.
Fasting triglycerides above upper limit of normal at Screening.
Any gastrointestinal complaints within 7 days prior to first dosing.